The U.S. exoskeleton market size was estimated at USD 234.18 million in 2025 and is projected to reach USD 640.25 million by 2033, growing at a CAGR of 13.09% from 2026 to 2033. The rapidly growing geriatric population, rising adoption of medical devices across industries such as automotive, military, defense, and construction, and the rising incidence of stroke are key drivers of growth in the U.S. exoskeleton industry.
The growing incidence rate of traumatic spinal cord injuries (SCI) is expected to drive the demand across U.S. markets. For instance, in September 2025, the United Spinal Association reported that 250,000 to 390,000 people in the U.S. are living with spinal cord injury, with about 18,000 new cases each year, most often due to vehicle accidents and falls. It highlighted common secondary complications, including depression, chronic pain, spasticity, pressure injuries, and bowel, bladder, and respiratory issues.
Exoskeleton solutions are increasingly being adopted to support mobility restoration and rehabilitation, particularly for individuals with spinal cord injuries. In the U.S., ongoing innovation in wearable robotics is encouraging manufacturers to introduce next-generation systems with improved personalization and digital integration. For instance, in 2025, Lifeward Ltd. announced the nationwide U.S. commercialization of its latest personal exoskeleton, ReWalk 7. The new system incorporates advanced features such as cloud-based connectivity, adaptive software, and adjustable walking speeds, enabling a more tailored gait experience for users with spinal cord injuries. This launch reflects the company’s strategic focus on enhancing user autonomy, clinical outcomes, and real-world usability of exoskeleton-assisted walking solutions in the U.S. market.
“The ReWalk 7 was developed over several years, integrating advanced technological innovations with feedback from clinicians and patients to build upon the ReWalk’s world-class reputation for industry leadership, The result is a device that is optimized for real-world use, with an unmatched user experience and freedom of movement. We are thrilled to be able to provide paralyzed individuals across the country with a new option for integrating walking to everyday life.” -Larry Jasinski, CEO of Lifeward
The increasing prevalence of traumatic spinal cord injury is boosting the growth of the U.S. exoskeleton market, as patients suffering from spinal cord injury are recommended to use an exoskeleton to improve their condition. This has become a key driver for the adoption of exoskeletons by patients and healthcare providers. For instance, as per the National Spinal Cord Injury Statistical Center (NSCISC) in 2024, in the U.S., traumatic spinal cord injury remains a significant public health concern, with recent estimates indicating that approximately 18,400 new cases are reported each year. This incident corresponds to around 54 newly diagnosed individuals per one million people annually, underscoring the persistent risk of severe spinal trauma across the population. The steady occurrence of these injuries reflects ongoing exposure to factors such as road traffic accidents, falls, sports-related injuries, and workplace incidents, contributing to a sustained patient pool requiring long-term rehabilitation, mobility assistance, and advanced supportive technologies.
Some of the most common musculoskeletal injuries and disorders affecting workers in physically demanding sectors such as construction include occupational overuse syndrome (OOS), cumulative trauma disorders (CTD), and repetitive strain injury (RSI). These conditions arise from repetitive motions, heavy lifting, awkward postures, and prolonged exertion on the job. According to the most recent data from the U.S. Bureau of Labor Statistics in August 2023, an estimated 502,380 workplace musculoskeletal disorder cases were reported over the 2021-2022 period, with an incidence rate of about 25.3 cases per 10,000 full-time equivalent workers, illustrating the widespread nature of these injuries across U.S. industries.
In addition, as per the WorkCare, Inc. article published in March 2025, broader estimates suggest that musculoskeletal disorders account for over 1 million workplace injuries in the U.S. annually, placing a substantial burden on employers and workers alike. These high rates of work-related musculoskeletal issues are key drivers for the growing adoption of exoskeleton solutions, as such technology can help augment or support physical tasks, improve worker health and productivity, and reduce fatigue among industrial laborers.
Rapid technological advancements in the U.S. exoskeleton market are driving innovation, accelerating adoption across health care, industrial, and consumer segments. For instance, in January 2026, a key development in the U.S. is the recent unveiling of new AI-enabled wearable robotic systems at major trade events such as CES 2026, where several companies showcased next-generation portable exoskeletons that incorporate real-time AI-driven assistance, including terrain adaptive controls and compact, user-centric designs that support mobility and reduce physical exertion for diverse users. These products signal a shift toward more intelligent, adaptive exoskeleton solutions designed to assist both daily mobility and demanding tasks, reflecting growing interest and commercial momentum in the U.S. wearable robotics space.
This product will be delivered within 1-3 business days.
The growing incidence rate of traumatic spinal cord injuries (SCI) is expected to drive the demand across U.S. markets. For instance, in September 2025, the United Spinal Association reported that 250,000 to 390,000 people in the U.S. are living with spinal cord injury, with about 18,000 new cases each year, most often due to vehicle accidents and falls. It highlighted common secondary complications, including depression, chronic pain, spasticity, pressure injuries, and bowel, bladder, and respiratory issues.
Exoskeleton solutions are increasingly being adopted to support mobility restoration and rehabilitation, particularly for individuals with spinal cord injuries. In the U.S., ongoing innovation in wearable robotics is encouraging manufacturers to introduce next-generation systems with improved personalization and digital integration. For instance, in 2025, Lifeward Ltd. announced the nationwide U.S. commercialization of its latest personal exoskeleton, ReWalk 7. The new system incorporates advanced features such as cloud-based connectivity, adaptive software, and adjustable walking speeds, enabling a more tailored gait experience for users with spinal cord injuries. This launch reflects the company’s strategic focus on enhancing user autonomy, clinical outcomes, and real-world usability of exoskeleton-assisted walking solutions in the U.S. market.
“The ReWalk 7 was developed over several years, integrating advanced technological innovations with feedback from clinicians and patients to build upon the ReWalk’s world-class reputation for industry leadership, The result is a device that is optimized for real-world use, with an unmatched user experience and freedom of movement. We are thrilled to be able to provide paralyzed individuals across the country with a new option for integrating walking to everyday life.” -Larry Jasinski, CEO of Lifeward
The increasing prevalence of traumatic spinal cord injury is boosting the growth of the U.S. exoskeleton market, as patients suffering from spinal cord injury are recommended to use an exoskeleton to improve their condition. This has become a key driver for the adoption of exoskeletons by patients and healthcare providers. For instance, as per the National Spinal Cord Injury Statistical Center (NSCISC) in 2024, in the U.S., traumatic spinal cord injury remains a significant public health concern, with recent estimates indicating that approximately 18,400 new cases are reported each year. This incident corresponds to around 54 newly diagnosed individuals per one million people annually, underscoring the persistent risk of severe spinal trauma across the population. The steady occurrence of these injuries reflects ongoing exposure to factors such as road traffic accidents, falls, sports-related injuries, and workplace incidents, contributing to a sustained patient pool requiring long-term rehabilitation, mobility assistance, and advanced supportive technologies.
Some of the most common musculoskeletal injuries and disorders affecting workers in physically demanding sectors such as construction include occupational overuse syndrome (OOS), cumulative trauma disorders (CTD), and repetitive strain injury (RSI). These conditions arise from repetitive motions, heavy lifting, awkward postures, and prolonged exertion on the job. According to the most recent data from the U.S. Bureau of Labor Statistics in August 2023, an estimated 502,380 workplace musculoskeletal disorder cases were reported over the 2021-2022 period, with an incidence rate of about 25.3 cases per 10,000 full-time equivalent workers, illustrating the widespread nature of these injuries across U.S. industries.
In addition, as per the WorkCare, Inc. article published in March 2025, broader estimates suggest that musculoskeletal disorders account for over 1 million workplace injuries in the U.S. annually, placing a substantial burden on employers and workers alike. These high rates of work-related musculoskeletal issues are key drivers for the growing adoption of exoskeleton solutions, as such technology can help augment or support physical tasks, improve worker health and productivity, and reduce fatigue among industrial laborers.
Rapid technological advancements in the U.S. exoskeleton market are driving innovation, accelerating adoption across health care, industrial, and consumer segments. For instance, in January 2026, a key development in the U.S. is the recent unveiling of new AI-enabled wearable robotic systems at major trade events such as CES 2026, where several companies showcased next-generation portable exoskeletons that incorporate real-time AI-driven assistance, including terrain adaptive controls and compact, user-centric designs that support mobility and reduce physical exertion for diverse users. These products signal a shift toward more intelligent, adaptive exoskeleton solutions designed to assist both daily mobility and demanding tasks, reflecting growing interest and commercial momentum in the U.S. wearable robotics space.
U.S. Exoskeleton Market Report Segmentation
This report forecasts revenue and volume growth at the country level and provides an analysis of industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the U.S. exoskeleton market report based on mobility, technology, extremity, end-use, and region:- Mobility Outlook (Volume, 000' Units; Revenue, USD Million, 2021-2033)
- Mobile
- Fixed/Stationary
- Technology Outlook (Volume, 000' Units; Revenue, USD Million, 2021-2033)
- Powered
- Non-powered
- Extremity Outlook (Volume, 000' Units; Revenue, USD Million, 2021-2033)
- Upper Body
- Lower Body
- Full Body
- End-use Outlook (Volume, 000' Units; Revenue, USD Million, 2021-2033)
- Healthcare
- Military
- Industry
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Exoskeleton Market Variables, Trends & Scope
Chapter 4. U.S. Exoskeleton Market Segment Analysis, By Mobility 2021-2033 (USD Million), Unit Volume (000’ Units)
Chapter 5. U.S. Exoskeleton Market Segment Analysis, By Technology 2021-2033 (USD Million), Unit Volume (000’ Units)
Chapter 6. U.S. Exoskeleton Market Segment Analysis, By Extremity 2021-2033 (USD Million), Unit Volume (000’ Units)
Chapter 7. U.S. Exoskeleton Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Exoskeleton market report include:- Ekso Bionics
- Lockheed Martin Corporation
- Suit X
- Rex Bionics Plc.
- ReWalk Robotics
- DIH Medical
- German Bionic
- Sarcos Technology and Robotics Corporation
- Parker Hannifin Corporation
- Bionik Laboratories
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | February 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 234.18 Million |
| Forecasted Market Value ( USD | $ 640.25 Million |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
